23:22:19 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

Iconovo

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-24 Kvartalsrapport 2024-Q3
2024-07-12 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning ICO 0.00 SEK
2024-04-25 Kvartalsrapport 2024-Q1
2024-03-06 Extra Bolagsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-10-27 Extra Bolagsstämma 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-07-14 Kvartalsrapport 2023-Q2
2023-05-23 Ordinarie utdelning ICO 0.00 SEK
2023-05-22 Årsstämma 2023
2023-04-28 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-10-28 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning ICO 0.00 SEK
2022-05-17 Årsstämma 2022
2022-04-29 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-20 Ordinarie utdelning ICO 0.00 SEK
2021-05-19 Årsstämma 2021
2021-04-29 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-10-27 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning ICO 0.00 SEK
2020-05-08 Kvartalsrapport 2020-Q1
2020-05-08 Årsstämma 2020
2020-03-11 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-16 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning ICO 0.00 SEK
2019-05-15 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-10 Kvartalsrapport 2018-Q2
2018-05-16 Årsstämma 2018
2018-04-19 Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Iconovo är verksamt inom medicinteknik. Bolaget utvecklar inhalatorer för medicinskt bruk. Bolagets produkter används vid behandling utav astma och kol, där inhalatorerna består av pulverbaserat läkemedel. Produkterna licensieras ut och säljs under varierade varumärken. Utöver produktutveckling återfinns kompetens inom läkemedelsformulering. Bolaget grundades under 2013 och har sitt huvudkontor i Lund.
Stevanato to invest in ICOcap® manufacturing
2020-07-02 10:35:00

Stevanato announced in their industrial plan for 2020 – 2023 that they intend to invest almost Euro 400 million in manufacturing and R&D programs for drug delivery systems. A share of this investment will be allocated to the manufacturing of ICOcap®. This update follows the announcement May 27 that ICOcap® received a CE-mark.

Stevanato also recently launched a new product site to increase the visibility of ICOcap® underlining its position as an important product for the future, where Iconovo is featured as a service provider for customizations and formulation services.  

To find the press release for Stevanato’s industrial plan: https://www.stevanatogroup.com/news-events/press-releases/stevanato-group-planned-investments-under-the-2020-2023-industrial-plan-about-400-million-euros-to-finance-the-company-development/

To find Stevanato’s new ICOcap® site: https://www.stevanatogroup.com/drug-delivery-devices/icocap/

To read more about the CE-mark of ICOcap®: https://iconovo.se/capsule-inhaler-icocap-from-iconovo-ce-marked-for-clinical-trials/

Contacts

Johan Wäborg, CEO
+46 707 78 51 71
johan.waborg@iconovo.se

About Iconovo

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled
drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company’s Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: certifiedadviser@penser.se.

Attachments

Stevanato to invest in ICOcap® manufacturing

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden